Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Robert I., Gleeson, Michelle L., Mikhael, Joseph, Danese, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434403/
https://www.ncbi.nlm.nih.gov/pubmed/22969803
http://dx.doi.org/10.1155/2012/978391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434403/
https://www.ncbi.nlm.nih.gov/pubmed/22969803
http://dx.doi.org/10.1155/2012/978391

Ejemplares similares